Association of mannose-binding lectin, ficolin-2 and immunoglobulin concentrations with future exacerbations in patients with chronic obstructive pulmonary disease: secondary analysis of the randomized controlled REDUCE trial.
Severin VogtJörg D LeuppiPhilipp SchuetzBeat MuellerCarmen VolkenSarah DrägerMarten TrendelenburgJonas RutishauserMichael OsthoffPublished in: Respiratory research (2021)
MBL modified the short-term exacerbation risk after a recent acute exacerbation of COPD, particularly in the setting of concurrent IgG deficiency and recent prolonged systemic glucocorticoid treatment. Ficolin-2 did not emerge as a predictor of a future exacerbation risk.
Keyphrases
- chronic obstructive pulmonary disease
- lung function
- phase iii
- respiratory failure
- phase ii
- clinical trial
- current status
- open label
- liver failure
- study protocol
- squamous cell carcinoma
- cystic fibrosis
- drug induced
- intensive care unit
- randomized controlled trial
- air pollution
- placebo controlled
- extracorporeal membrane oxygenation
- rectal cancer
- aortic dissection